Pharmacological Inhibition of SLC33A1 Promotes Endoplasmic Reticulum Hyperoxidation and Induces Adaptive IRE1/XBP1s Signaling
This study identifies IXA4 as the first pharmacologic inhibitor of SLC33A1, demonstrating that its binding to the transporter disrupts ER glutathione homeostasis to induce adaptive IRE1/XBP1s signaling and selectively kill KEAP1-deficient lung adenocarcinoma cells.